Potential Biomarkers in Systemic Lupus Erythematosus

Area of Science:

• Immunology
• Rheumatology
• Biomarker Discovery

Background:

• Systemic lupus erythematosus (SLE) is a complex autoimmune disease with variable clinical presentations.
• Current biomarkers for SLE disease activity, such as anti-dsDNA antibodies and complement levels, have limitations.
• Many SLE patients experience recurrent disease flares despite available treatments.

Purpose of the Study:

• To review established and emerging biomarkers for SLE diagnosis and monitoring.
• To explore the potential of immune cell subsets as biomarkers for SLE activity.
• To discuss the role of cytokines, chemokines, autoantibodies, and complement in SLE management.

Main Methods:

• Literature review of current research on SLE biomarkers.
• Analysis of immune cell subsets (plasmacytoid dendritic cells, T cells, B cells) in relation to SLE activity.
• Examination of non-cellular biomarkers including cytokines, chemokines, autoantibodies, and complement.

Main Results:

• Imbalances in specific immune cell populations correlate with SLE disease activity and organ involvement.
• Emerging biomarkers show promise in improving the accuracy of SLE monitoring.
• Established biomarkers like anti-dsDNA and complement have known limitations in reflecting real-time disease status.

Conclusions:

• Reliable biomarkers are essential for personalized SLE treatment strategies.
• Validated biomarkers will enhance clinical decision-making for treatment selection and glucocorticoid tapering.
• Improved biomarker identification can lead to better prediction of disease remission and more effective SLE management.